Dr. Ruby Greywoode, MD
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,960 | 4 | 88.4% |
| Food and Beverage | $853.99 | 9 | 9.5% |
| Education | $189.02 | 2 | 2.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $7,971 | 5 | $0 (2024) |
| ABBVIE INC. | $416.38 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $135.00 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $133.80 | 2 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $125.00 | 1 | $0 (2018) |
| Janssen Research & Development, LLC | $122.38 | 1 | $0 (2024) |
| Aries Pharmaceuticals, Inc. | $99.02 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,296 | 9 | PFIZER INC. ($7,971) |
| 2018 | $125.00 | 1 | Janssen Scientific Affairs, LLC ($125.00) |
| 2017 | $582.00 | 5 | AbbVie, Inc. ($392.98) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/05/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $43.80 | General |
| Category: Immunology | ||||||
| 08/22/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/22/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/20/2024 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $122.38 | General |
| 05/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| 05/18/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $23.40 | General |
| 01/23/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/06/2018 | Janssen Scientific Affairs, LLC | STELARA (Biological), REMICADE | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 10/15/2017 | Aries Pharmaceuticals, Inc. | MB MMX (Drug), ELEVIEW | Education | In-kind items and services | $99.02 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/19/2017 | AbbVie, Inc. | Viekira (Drug) | Food and Beverage | In-kind items and services | $145.00 | General |
| Category: Virology | ||||||
| 09/14/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $123.08 | General |
| 07/26/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $124.90 | General |
| 05/04/2017 | Janssen Biotech, Inc. | REMICADE (Biological) | Education | In-kind items and services | $90.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 2 |
| XELJANZ CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,560 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 30 | 40 | $25,975 | $3,075 |
| 2022 | 4 | 80 | 85 | $92,766 | $9,376 |
| 2021 | 3 | 70 | 78 | $68,286 | $7,785 |
| 2020 | 2 | 34 | 37 | $35,980 | $4,239 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 25 | $12,625 | $1,889 | 15.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 15 | 15 | $13,350 | $1,186 | 8.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 33 | 33 | $37,521 | $4,189 | 11.2% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 22 | 22 | $19,580 | $2,057 | 10.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 19 | $9,595 | $1,692 | 17.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $26,070 | $1,438 | 5.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 32 | 32 | $36,541 | $4,027 | 11.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 25 | 25 | $21,570 | $2,384 | 11.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 21 | $10,175 | $1,373 | 13.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 18 | 19 | $21,847 | $2,477 | 11.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 16 | 18 | $14,133 | $1,761 | 12.5% |
About Dr. Ruby Greywoode, MD
Dr. Ruby Greywoode, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2012. The National Provider Identifier (NPI) number assigned to this provider is 1972861300.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruby Greywoode, MD has received a total of $9,003 in payments from pharmaceutical and medical device companies, with $8,296 received in 2024. These payments were reported across 15 transactions from 7 companies. The most common payment nature is "" ($7,960).
As a Medicare-enrolled provider, Greywoode has provided services to 214 Medicare beneficiaries, totaling 240 services with total Medicare billing of $24,474. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Internal Medicine
- Location New York, NY
- Active Since 04/23/2012
- Last Updated 09/24/2013
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1972861300
Products in Payments
- XELJANZ (Drug) $7,971
- Viekira (Drug) $145.00
- STELARA (Biological) $125.00
- MB MMX (Drug) $99.02
- REMICADE (Biological) $90.00
- TREMFYA (Drug) $43.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in New York
Dr. Saakshi Khattri, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $1.7M
Cheguevara Afaneh, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $1.5M
John Allan, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $550,557
Jose Scher, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $496,980
Dr. Anthony Rossi, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $442,377
Anuradha Lala-Trindade
Student in an Organized Health Care Education/Training Program — Payments: $284,341